Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)

Journal of Hepatology(2026)10.1016/j.jhep.2026.02.019Source: DataRank Database

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL) is a research paper published in Journal of Hepatology (2026). On theSindex it has a DataRank of 0.345. It has been cited 9 times.

N/A

0.345DataRank · unranked

Scored on demand from live citation data

9 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 43.32)OA: closedTopics (25)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.345

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (22)

Licia Rivoltini ORCID,David J. Pinato ORCID,Valentina Bellia,Marianna Maspero ORCID,Marco Bongini

Live enrichment

PubMed:41763363 OpenAlex:https://openalex.org/W7131667797

Associazione Italiana per la Ricerca sul Cancro

Grant: 2022 ID 27841

Associazione Italiana per la Ricerca sul Cancro

Grant: 2023-01

Ministero della Salute

Imperial Experimental Cancer Medicine Centre

National Institute for Health Research (NIHR)

National Institute on Handicapped Research

Cancer Treatment and Research Trust

NIHR Imperial Biomedical Research Centre

FWCI

43.32

Citation Percentile

1.0%

Citation Trend

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S016882782600084X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S016882782600084X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jhep.2026.02.019

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41763363

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyCholangiocarcinoma and Gallbladder Cancer Studies

MeSH Terms

BevacizumabBridge TherapyAgedFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingProspective StudiesLiver TransplantationTreatment OutcomeAntibodies, Monoclonal, Humanized

Keywords

Hepatocellular carcinomaLiver transplantationCarcinomaComplete responseOrthotopic liver transplantationDownstagingTransplant OncologyImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)

FAIR Checklist

DataRank Breakdown

Authors (22)

Funding (8 grants)

Impact

Open Access

Topics